Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis;Mukosaschutz durch Phosphatidylcholin als neues therapeutisches Prinzip bei der Colitis ulcerosa

Zeitschrift fur Gastroenterologie

Volumn 51, Issue 4, 2013, Pages 384-389

  Stremmel, W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

lecithin; mucosal barrier; mucus; phosphatidylcholine; ulcerative colitis

Indexed keywords

PHOSPHATIDYLCHOLINE;

ARTICLE; ILEUM MUCOSA; MUCUS; NONHUMAN; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; HUMANS; INTESTINAL MUCOSA; MODELS, BIOLOGICAL; PHOSPHATIDYLCHOLINES;

EID: 84876220788     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1335042     Document Type: Article

References (31)

1. Podolsky D. Inflammatory bowel disease. N Engl J Med: 2002; 347 417 429
2. Backhed F., Ley R. E., Sonnenburg J. L. et al. Host-bacterial mutualism in the human intestine. Science: 2005; 307 1915 1920
3. Gerseman M., Wehkamp J., Stange E. F. Innate immune dysfunction in inflammatory bowel disease. Intern Med J: 2012; 271 5 421 428
4. Becker T., Loch G., Beyer M. et al. FOXO-dependent regulation of innate immune homeostasis. Nature: 2010; 463 369 373
5. Atuma C., Strugala V., Allen A. et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol: 2001; 280 G922 G929
6. Shirazi T., Longman R. J., Corfield A. P. et al. Mucins and inflammatory bowel disease. Postgrad Med J: 2000; 76 473 478
7. Johannson M. EV, Phillipson M., Petersson J. et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A: 2008; 105 15064 15069
8. Matsuo K., Ota H., Akamatsu T. et al. Histochemistry of the surface mucous gel layer of the human colon. Gut: 1997; 40 782 789
9. Hicks A. M., DeLong C. J., Thomas M. J. et al. Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta: 2006; 1761 1022 1029
10. Hills B. A. Surface-active phospholipid: a Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Intern Med J: 2002; 32 5 - 6 242 251
11. Lichtenberger L. M. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol: 1995; 57 565 583
12. Willumeit R., Schuster A., Iliev P. et al. Phospholipids as implant coatings. J Mater Sci Mater Med: 2007; 18 02 367 80
13. Ehehalt R., Jochims C., Lehmann W. D. et al. Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta: 2004; 1682 63 71
14. Engle M. J., Grove M. L., Becich M. J. et al. Appearance of surfactant-like particles in apical medium of Caco-2 cells may occur via tight junctions. Am J Physiol: 1995; 268 C1401 C1413
15. Ehehalt R., Wagenblast J., Erben G. et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol: 2004; 39 08 737 742
16. Braun A., Treede I., Gotthardt D. et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis: 2009; 15 1705 1720
17. Braun A., Schoenfeld U., Welsch T. et al. Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis: 2011; 26 898 998
18. Meves A., Stremmel C., Gottschalk K. et al. The kindling protein family: new members to the club of focal adhesion proteins. Trends Cell Biol: 2009; 19 504 512
19. Ussar S., Moser M., Widmaier M. et al. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet: 2008; 4 e1000289
20. Gibson P. R., Muir J. G. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut: 2005; 54 900 903
21. Nazareth M., Mahadevan U. Phosphatidylcholine in steroid refractory chronic ulcerative colitis - is it all in the mucus? Ann Intern Med: 2007; 147 603 610
22. Karner M., Ehehalt R., Stremmel W. Retarded release phosphatidylcholine: A new therapeutic option for ulcerative colitis. In: Dignass A., Rachmilewitz D., Stange EF. et al.eds. Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation. Heidelberg, Dordrecht, New York Springer: 2007; 161 170
23. Anes E., Kühnel M. P., Bos E. et al. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat Cell Biol: 2003; 5 09 793 802 Epub 2003 Aug 24
24. Treede I., Braun A., Jeliaskova P. et al. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol: 2009; 13 09 53
25. Are A. F., Galkin V. E., Pospelova T. V. et al. The p65/RelA subunit of NF-kappaB interacts with actin-containing structures. Exp Cell Res: 2000; 256 02 533 44
26. Stremmel W., Merle U., Zahn A. et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut: 2005; 54 966 971
27. Stremmel W., Braun A., Hanemann A. et al. Delayed Release Phosphatidylcholine in Chronic-active Ulcerative Colitis: A Randomized, Double-blinded, Dose Finding Study. J Clin Gastroenterol: 2010; 44 05 e101 e107
28. Stremmel W., Ehehalt R., Autschbach F. et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med: 2007; 147 09 603 610
29. Karner M., Kocjan A., Stein J. et al. Modified Release Phosphatidylcholine "LT-02" in Active Ulcerative Colitis: a Randomized, Placebo-Controlled Multicentre Study. Gastroenterology: 2012; 142 05 01 211
30. Prantera C., Lochs H., Grimaldi M. et al. Retic Study Group (Rafaximin-Eir-Treatment in Crohn's Disease). Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderatley Active Crohn's Disease. Gastroenterology: 2012; 142 03 473 481
31. Travis S. P., Stange E. F., Lemann M. et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis: 2008; 2 01 24 62